Eisai, Salix team up to push Colazal

Share this article:
Salix Pharmaceuticals and Eisai have entered into a multi-year co-promotion deal to promote Salix's ulcerative colitis treatement Colazal (balsalazide disodium).

Financial terms of the deal were not disclosed.

Eisai's primary care and specialty sales forces will help Salix promote Colazal to primary care physicians and gastroenterologists. Approximately 600 Eisai sales reps will be added to the field force of 96 Salix reps, beginning in late October, an Eisai spokeswoman told MM&M.

Eisai also has exclusive rights to be involved in promotion of an 1100 mg. version of Colazal, pending product approval, Eisai said.  

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...